UAE Next Generation Sequencing Market By Product (Consumables, Platforms, Services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Single Molecule Real Time Sequencing, Others), By Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research, Others), By End User (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), By Region, Competition Forecast & Opportunities, 2027
UAE next generation sequencing market is anticipated to grow at a robust CAGR during the forecast period, 2023-2027. The increasing prevalence of cancer and the rise in the applications of next-generation sequencing in cancer treatment are the primary factors driving the growth of the UAE next-generation sequencing market. Also, ongoing advancements in next-generation sequencing platforms and support from the government for research and development activities are projected to play a significant role in accelerating the market demand in the next five years.
Increasing Prevalence of Cancer Drives the Market Growth
Cancer is one of the third leading causes of death in the UAE after trauma and cardiovascular diseases. Cancer is a type of heterogeneous disease and is caused due to accumulation of DNA mutations. Next-generation sequencing is increasingly adopted for cancer genomic research owing to the improvement and development of new sequencing technology. It is used to advance the personalized treatment of cancer and identify rare and novel cancer mutations. Next-generation sequencing is expected to significantly improve cancer diagnosis, treatment, and management as it can sequence human genomes and thousands of cancer genomes. The process helps to understand the molecular mechanism of oncogenesis and efficiently and accurately identify high-risk patients and chemotherapeutic drugs to cure the disease.
The government is focusing on improving the healthcare sector and providing quality care to patients. In 2019, UAE healthcare expenditure as a % of GDP was 4.27%. UAE has a solid economic resource that can be utilized to improve cancer care across the country. Emirates Oncology Society established a UAE Oncology Task Force in 2019 to treat the growing number of cancer patients. The rise in the adoption of unhealthy eating habits and sedentary lifestyles by people is expected to fuel the occurrence of cancer among patients. The increase in the use of next-generation sequencing technology by the market players to enhance the quality of care is expected to boost the growth of the UAE next-generation sequencing market through the forecast period.
Support from the Government in Next Generation Sequencing Technology
The UAE government is continuously working on advancing the healthcare sector and providing quality care to all of its citizens. Currently, healthcare services for free for all UAE citizens. Dubai Genetic center has extended its services and has added a genomics unit to implement next-generation sequencing technology for better disease diagnosis and treatment. Also, the government has established a board for the Emirati Genome Program and launched a Center for Genomic Discovery which is the first of its kind to provide personalized and personal healthcare for the Emirati population. The government's growing focus on improving cancer treatment facilities and services and allocating huge funds for cancer treatment is expected to boost the UAE next generation sequencing market growth for the next five years.
Technological Advancements in Next Generation Sequencing Platforms
Market players are investing in research and development activities to advance the existing infrastructure and find novel solutions to improve the results of next-generation sequencing. The introduction of easy-to-use and portable next-generation sequencing platforms which can provide quick and accurate test results is in high demand. Market players have started to focus on enhancing the precision of results obtained from next-generation platforms and increasing the funds for research and development activities which is expected to create lucrative growth opportunities for UAE next-generation sequencing market in the forecast period.
Market Segmentation
The UAE next-generation sequencing market is segmented into product, technology, application, end-user, regional distribution, and company. Based on product, the market is divided into consumables, platforms, and services. Based on technology, the market is divided into sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, single molecule real-time sequencing, and others. Based on application, the market is divided into biomarkers & cancer, diagnostics, reproductive health, personalized medicine, agriculture & animal research, and others. Based on end users, the market is divided into academic & clinical research centers, pharmaceutical & biotechnology companies, hospitals & clinics, and others. To analyze the market based on the region, the UAE next-generation sequencing market is studied in major regions namely Dubai, Abu Dhabi, Sharjah, and Rest of the UAE.
Market Players
Oxford Nanopore UAE, Agiomix Labs, Illumina UAE, Thermo Fischer Scientific UAE, PerkinElmer UAE, and Alliance Global UAE, are among the major market players operating in the UAE next-generation sequencing market.
Report Scope:
In this report, UAE next-generation sequencing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook